Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Nov;107(11):991-1002.
doi: 10.1007/s00392-018-1281-8. Epub 2018 May 19.

Safety and Feasibility of Pulmonary Artery Pressure-Guided Heart Failure Therapy: Rationale and Design of the Prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF)

Affiliations
Clinical Trial

Safety and Feasibility of Pulmonary Artery Pressure-Guided Heart Failure Therapy: Rationale and Design of the Prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF)

Christiane E Angermann et al. Clin Res Cardiol. .

Abstract

Background: Wireless monitoring of pulmonary artery (PA) pressures with the CardioMEMS HF™ system is indicated in patients with New York Heart Association (NYHA) class III heart failure (HF). Randomized and observational trials have shown a reduction in HF-related hospitalizations and improved quality of life in patients using this device in the United States.

Objective: MEMS-HF is a prospective, non-randomized, open-label, multicenter study to characterize safety and feasibility of using remote PA pressure monitoring in a real-world setting in Germany, The Netherlands and Ireland.

Methods and results: After informed consent, adult patients with NYHA class III HF and a recent HF-related hospitalization are evaluated for suitability for permanent implantation of a CardioMEMS™ sensor. Participation in MEMS-HF is open to qualifying subjects regardless of left ventricular ejection fraction (LVEF). Patients with reduced ejection fraction must be on stable guideline-directed pharmacotherapy as tolerated. The study will enroll 230 patients in approximately 35 centers. Expected duration is 36 months (24-month enrolment plus ≥ 12-month follow-up). Primary endpoints are freedom from device/system-related complications and freedom from pressure sensor failure at 12-month post-implant. Secondary endpoints include the annualized rate of HF-related hospitalization at 12 months versus the rate over the 12 months preceding implant, and health-related quality of life. Endpoints will be evaluated using data obtained after each subject's 12-month visit.

Conclusions: The MEMS-HF study will provide robust evidence on the clinical safety and feasibility of implementing haemodynamic monitoring as a novel disease management tool in routine out-patient care in selected European healthcare systems.

Trial registration: ClinicalTrials.gov; NCT02693691.

Keywords: CardioMEMS™ system; Heart failure; Hospitalization; Pulmonary artery pressure; Quality of life; Safety.

Similar articles

See all similar articles

Cited by 14 articles

See all "Cited by" articles

References

    1. J Gen Intern Med. 2001 Sep;16(9):606-13 - PubMed
    1. Am Heart J. 2007 Aug;154(2):260-6 - PubMed
    1. Circ Heart Fail. 2012 Jan;5(1):25-35 - PubMed
    1. Circ Heart Fail. 2017 Jan;10(1): - PubMed
    1. Lancet. 2011 Feb 19;377(9766):658-66 - PubMed

Associated data

LinkOut - more resources

Feedback